Lam Research Corporation vs Manulife Financial Corporation — how do they compare? Lam Research Corporation trades at $324.4 (market cap $383.63B), while Manulife Financial Corporation trades at $42.5 (market cap $69.96B). The key difference: Lam Research Corporation is far larger — about 5.5× Manulife Financial Corporation's market cap, and Manulife Financial Corporation pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| LRCX | MFC | |
|---|---|---|
Market Cap | $383.63B | $69.96B |
Sector | Technology | Financials |
52-Week High | $433.33 | $43.39 |
52-Week Low | $94.84 | $29.90 |
Enterprise Value | $382.61B | $66.52B |
Dividend Yield | 0.34% | 3.14% |
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $306.96, down 2.02% amid semiconductor sector weakness. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $1.47 versus $1.36 expected, continuing a pattern of earnings outperformance. Valuation metrics remain elevated with P/E at 59.22 and P/S at 18.3, reflecting premium pricing for AI-driven growth prospects. Technical indicators show bearish momentum with price testing key support at $306.
Outlook remains positive based on analyst consensus with $393 price target (78% buy ratings), though near-term risks include semiconductor cycle volatility and rich valuations. The company's positioning in AI chip manufacturing equipment and strong cash flow generation ($6.17B operating cash flow in 2025) supports long-term growth potential despite sector headwinds.
Manulife Financial (MFC) trades at $42.56, down 1.91% today but remains near 52-week highs. The stock shows strong fundamentals with revenue growth from $46.2B in 2024 to $53.0B in 2025 and consistent profitability (12.07% net margin). Technical indicators are mixed with bullish moving averages but overbought RSI levels. Recent Q1 2026 earnings missed expectations despite strong Asia performance, while analyst consensus remains bullish with 57% buy ratings.
MFC presents a compelling value case with reasonable valuation (P/E 17.75) and dividend yield support. Key opportunities include AI integration partnerships and Asia growth, though risks include wealth management outflows and regulatory scrutiny. The stock's current technical overbought condition suggests potential near-term consolidation before resuming upward trajectory.
Trailing returns across standard periods
Latest headlines on both assets
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →